We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
Roche's Tarceva and AstraZeneca's own Iressa are the current standard of care in first line treatments of patients with locally advanced or metastatic EGFR+ lung cancer, but Tagrisso looks set to ...
NICE said there is clinical trial evidence showing that Tagrisso stalls cancer growth longer than treatment with two older EGFR drugs, Roche’s Tarceva (erlotinib) and AZ’s Iressa (gefitinib).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback